Trading of Spruce Biosciences was halted at 10:56 AM EST due to "LULD pause". Spruce Biosciences (SPRB) Competitors $182.60 +52.20 (+40.03%) Closing price 04:00 PM EasternExtended Trading$163.00 -19.60 (-10.73%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. CTXR, FNCH, SYBX, PRPH, ABP, LEXX, CLRB, THAR, LPTX, and EDSAShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Citius Pharmaceuticals (CTXR), Finch Therapeutics Group (FNCH), Synlogic (SYBX), ProPhase Labs (PRPH), Abpro (ABP), Lexaria Bioscience (LEXX), Cellectar Biosciences (CLRB), Tharimmune (THAR), Leap Therapeutics (LPTX), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors Citius Pharmaceuticals Finch Therapeutics Group Synlogic ProPhase Labs Abpro Lexaria Bioscience Cellectar Biosciences Tharimmune Leap Therapeutics Edesa Biotech Spruce Biosciences (NASDAQ:SPRB) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do analysts recommend SPRB or CTXR? Spruce Biosciences currently has a consensus price target of $131.25, indicating a potential downside of 28.12%. Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 3,685.71%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Spruce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Citius Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media favor SPRB or CTXR? In the previous week, Spruce Biosciences had 31 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 31 mentions for Spruce Biosciences and 0 mentions for Citius Pharmaceuticals. Spruce Biosciences' average media sentiment score of 0.13 beat Citius Pharmaceuticals' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Overall Sentiment Spruce Biosciences Neutral Citius Pharmaceuticals Neutral Do institutionals and insiders hold more shares of SPRB or CTXR? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is SPRB or CTXR more profitable? Citius Pharmaceuticals' return on equity of -60.03% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce BiosciencesN/A -177.45% -118.06% Citius Pharmaceuticals N/A -60.03%-33.83% Which has more risk & volatility, SPRB or CTXR? Spruce Biosciences has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Which has higher valuation & earnings, SPRB or CTXR? Citius Pharmaceuticals has lower revenue, but higher earnings than Spruce Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$1.30M79.00-$53.04M-$86.21-2.12Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A SummaryCitius Pharmaceuticals beats Spruce Biosciences on 7 of the 12 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.62M$1.05B$6.10B$10.53BDividend YieldN/A4.84%5.51%4.66%P/E Ratio-2.121.2885.6826.85Price / Sales79.0030.43584.82185.94Price / CashN/A17.6426.3031.10Price / Book3.487.6513.256.72Net Income-$53.04M-$7.66M$3.30B$276.44M7 Day Performance1,940.22%30.55%4.70%3.13%1 Month Performance1,928.89%32.68%8.43%10.21%1 Year Performance439.84%73.53%88.01%40.35% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences0.631 of 5 stars$182.60+40.0%$131.25-28.1%+281.4%$102.62M$1.30M-2.1220Trending NewsGap UpTrading HaltedHigh Trading VolumeCTXRCitius Pharmaceuticals2.0412 of 5 stars$1.17-1.3%$53.00+4,449.4%-87.7%$19.82MN/A0.0020Gap UpFNCHFinch Therapeutics Group0.8057 of 5 stars$12.25+0.3%N/A+3.8%$19.67MN/A-1.39190News CoverageSYBXSynlogicN/A$1.67-4.3%N/A+11.6%$19.43M$10K-20.7680Positive NewsPRPHProPhase Labs0.4397 of 5 stars$0.44+0.7%N/A-75.8%$18.32M$5.59M-0.35130Gap UpABPAbpro2.7679 of 5 stars$0.23-12.4%$4.00+1,677.8%N/A$18.04M$183K0.0015LEXXLexaria Bioscience2.601 of 5 stars$0.92-6.9%$4.00+337.2%-73.7%$17.90M$460K-1.377CLRBCellectar Biosciences2.4832 of 5 stars$5.40-0.3%$375.00+6,849.6%-90.7%$17.53MN/A-0.2810News CoverageGap DownTHARTharimmune2.7559 of 5 stars$2.97+2.3%$17.00+473.0%+40.9%$17.49MN/A-0.492News CoveragePositive NewsLPTXLeap Therapeutics2.6588 of 5 stars$0.42+15.9%$3.38+709.4%-70.2%$17.28MN/A-0.2640News CoverageGap DownEDSAEdesa Biotech2.5685 of 5 stars$2.45-0.2%$5.00+104.5%-32.4%$17.21MN/A-1.8520Positive News Related Companies and Tools Related Companies Citius Pharmaceuticals Competitors Finch Therapeutics Group Competitors Synlogic Competitors ProPhase Labs Competitors Abpro Competitors Lexaria Bioscience Competitors Cellectar Biosciences Competitors Tharimmune Competitors Leap Therapeutics Competitors Edesa Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
